Innovation

Peptides and aptamers thereof as specific modulators of mutant P53 function

Universita' degli studi di Trieste
posted on 02/08/2011

The invention relates to a group of small molecules – new peptides and aptamers – able to block the action of a mutant protein, whose name is mutant p53, which is involved in many aspects of tumor development and aggressiveness. The identified molecules are able to bind and neutralize mutant p53, thus killing cancer cells that express it.

Suggested Uses

The peptides related to the invention represent a starting point to design or screen for peptido-mimetic drugs able to target and kill cancer cells which express mutant p53, to be tested in clinical trials.

Advantages

The molecules related to the invention specifically recognize, bind and inhibit the tumor promoting factor mutant p53. Providing a new approach for treatment of tumors by specifically acting on mutant p53 give the advantage to develop new and very selective therapeutic strategies against tumors.

Innovation Details
 

Detailed Description

p53 mutants have an active role of in promoting tumorigenesis and different effort have been addressed to identify new strategies being able to inactivate their oncogenic function or to restore wild-type function of the protein. In this regard, researchers at the University of Trieste and LNCIB of Trieste identified a series of peptides and aptamers able to bind p53 structural and conformational mutants. In the breast cancer cell lines where the inventors tested these molecules, they acted as functional inhibitors of mutant p53-associated pro-oncogenic functions, providing the first evidences for further research and development.

Limitations

The clinical implications of the invention are restricted to those tumors expressing mutant p53. However, mutations in TP53 gene are among the most frequent genetic alteration in human cancer.

File Number: PCT/EP2008/053010 

Disease: Cancer


IP Protection

Patent Number(s): WO2009/112075

License Online

This innovation currently is not available for online licensing. Please contact Roberta Bensi at Universita' degli studi di Trieste for more information.

Request more info via email request more info
People

Case Manager:

Roberta Bensi Roberta Bensi

Innovations (5)


Download Technology Brief (PDF)


Followed By

Follow this innovation



No one is following this innovation.

Organization
Communities
Profile
Related Tags

Find more innovations


February 11, 2009

12,597 members 18,838 innovations 176 organizations

Browse

David Kolb, CEO and chairman of the board, Emunamedica LLC.

"We found tremendous value and benefit in using the iBridge Network..."  read more...